<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Med Inform</journal-id><journal-id journal-id-type="publisher-id">medinform</journal-id><journal-id journal-id-type="index">7</journal-id><journal-title>JMIR Medical Informatics</journal-title><abbrev-journal-title>JMIR Med Inform</abbrev-journal-title><issn pub-type="epub">2291-9694</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v13i1e72238</article-id><article-id pub-id-type="doi">10.2196/72238</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Prediction of Insulin Resistance in Nondiabetic Population Using LightGBM and Cohort Validation of Its Clinical Value: Cross-Sectional and Retrospective Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Peng</surname><given-names>Ting</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Miao</surname><given-names>Rujia</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names>Hao</given-names></name><degrees>BE</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names>Yanhui</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fan</surname><given-names>Duzhen</given-names></name><degrees>BE</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ren</surname><given-names>Jiayi</given-names></name><degrees>BE</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names>Jiangang</given-names></name><degrees>Prof Dr Med</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names>Yuan</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names>Jianwen</given-names></name><degrees>Prof Dr</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><institution>Health Management Center, Third Xiangya Hospital</institution><addr-line>Changsha</addr-line><country>China</country></aff><aff id="aff2"><institution>School of Mathematics and Statistics, Hunan University of Technology and Business</institution><addr-line>569 Yuelu District</addr-line><addr-line>Changsha</addr-line><country>China</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Coristine</surname><given-names>Andrew</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Lin</surname><given-names>Fangbo</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Xiao</surname><given-names>Le</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Jianwen Chen, Prof Dr, School of Mathematics and Statistics, Hunan University of Technology and Business, 569 Yuelu District, Changsha, 410205, China, 86 18692269664, 86 88618571; <email>chenjianwen0731@163.com</email></corresp><fn fn-type="equal" id="equal-contrib1"><label>*</label><p>these authors contributed equally</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>6</month><year>2025</year></pub-date><volume>13</volume><elocation-id>e72238</elocation-id><history><date date-type="received"><day>06</day><month>02</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>04</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>04</month><year>2025</year></date></history><copyright-statement>&#x00A9; Ting Peng, Rujia Miao, Hao Xiong, Yanhui Lin, Duzhen Fan, Jiayi Ren, Jiangang Wang, Yuan Li, Chen Jianwen. Originally published in JMIR Medical Informatics (<ext-link ext-link-type="uri" xlink:href="https://medinform.jmir.org">https://medinform.jmir.org</ext-link>), 13.6.2025. </copyright-statement><copyright-year>2025</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Medical Informatics, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://medinform.jmir.org/">https://medinform.jmir.org/</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://medinform.jmir.org/2025/1/e72238"/><abstract><sec><title>Background</title><p>Insulin resistance (IR), a precursor to type 2 diabetes and a major risk factor for various chronic diseases, is becoming increasingly prevalent in China due to population aging and unhealthy lifestyles. Current methods like the gold-standard hyperinsulinemic-euglycemic clamp has limitations in practical application. The development of more convenient and efficient methods to predict and manage IR in nondiabetic populations will have prevention and control value.</p></sec><sec><title>Objective</title><p>This study aimed to develop and validate a machine learning prediction model for IR in a nondiabetic population, using low-cost diagnostic indicators and questionnaire surveys.</p></sec><sec sec-type="methods"><title>Methods</title><p>A cross-sectional study was conducted for model development, and a retrospective cohort study was used for validation. Data from 17,287 adults with normal fasting blood glucose who underwent physical exams and completed surveys at the Health Management Center of Xiangya Third Hospital, Central South University, from January 2018 to August 2022, were analyzed. IR was assessed using the Homeostasis Model Assessment (HOMA-IR) method. The dataset was split into 80% (13,128/16,411) training and 20% (32,83/16,411) testing. A total of 5 machine learning algorithms, namely random forest, Light Gradient Boosting Machine (LightGBM), Extreme Gradient Boosting, Gradient Boosting Machine, and CatBoost were used. Model optimization included resampling, feature selection, and hyperparameter tuning. Performance was evaluated using <italic>F</italic><sub>1</sub>-score, accuracy, sensitivity, specificity, area under the curve (AUC), and Kappa value. Shapley Additive Explanations analysis was used to assess feature importance. For clinical implication investigation, a different retrospective cohort of 20,369 nondiabetic participants (from the Xiangya Third Hospital database between January 2017 and January 2019) was used for time-to-event analysis with Kaplan-Meier survival curves.</p></sec><sec sec-type="results"><title>Results</title><p>Data from 16,411 nondiabetic individuals were analyzed. We randomly selected 13,128 participants for the training group, and 3283 participants for the validation group. The final model included 34 lifestyle-related questionnaire features and 17 biochemical markers. In the validation group, their AUC were all greater than 0.90. In the test group, all AUC were also greater than 0.80. The LightGBM model showed the best IR prediction performance with an accuracy of 0.7542, sensitivity of 0.6639, specificity of 0.7642, <italic>F</italic><sub>1</sub>-score of 0.6748, Kappa value of 0.3741, and AUC of 0.8456. Top 10 features included BMI, fasting blood glucose, high-density lipoprotein cholesterol, triglycerides, creatinine, alanine aminotransferase, sex, total bilirubin, age, and albumin/globulin ratio. In the validation queue, all participants were separated into the high-risk IR group and the low-risk IR group according to the LightGBM algorithm. Out of 5101 high-risk IR participants, 235 (4.6%) developed diabetes, while 137 (0.9%) of 15,268 low-risk IR participants did. This resulted in a hazard ratio of 5.1, indicating a significantly higher risk for the high-risk IR group.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>By leveraging low-cost laboratory indicators and questionnaire data, the LightGBM model effectively predicts IR status in nondiabetic individuals, aiding in large-scale IR screening and diabetes prevention, and it may potentially become an efficient and practical tool for insulin sensitivity assessment in these settings.</p></sec></abstract><kwd-group><kwd>insulin resistance</kwd><kwd>machine learning</kwd><kwd>Light Gradient Boosting Machine</kwd><kwd>diabetes</kwd><kwd>diabetes prevention</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Insulin resistance (IR) refers to the reduced sensitivity or responsiveness of target organs such as the liver, skeletal muscles, or adipose tissue to insulin. In order to maintain normal blood glucose levels, the body compensates by secreting increased amounts of insulin [<xref ref-type="bibr" rid="ref1">1</xref>]. As a condition that can exist before the onset of type 2 diabetes, IR is not only one of the key mechanisms underlying the development of diabetes but also a major risk factor for various diseases [<xref ref-type="bibr" rid="ref2">2</xref>]. According to the International Diabetes Federation, it is estimated that by 2045, there will be 783.2 million people affected globally, with the vast majority having type 2 diabetes [<xref ref-type="bibr" rid="ref3">3</xref>]. Furthermore, IR is even more common. Data from the National Health and Nutrition Examination Survey in the United States show that approximately 40% of adults aged 18&#x2010;44 years have IR [<xref ref-type="bibr" rid="ref4">4</xref>]. A study in China revealed that the standardized prevalence of IR in adults aged 25 years or older is 29.22% [<xref ref-type="bibr" rid="ref5">5</xref>]. By scientifically assessing and managing IR, it is theoretically possible to effectively control the onset of diabetes. The first step is to identify IR. The high insulin clamp with normal blood glucose levels is considered the gold standard for assessing insulin sensitivity [<xref ref-type="bibr" rid="ref6">6</xref>]. However, in practice, this method is time-consuming, expensive, and difficult to apply widely. The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR; fasting glucose [mmol/L]&#x00D7;fasting insulin [&#x03BC;U/ml]/22.5) is regarded as an acceptable method for evaluating IR [<xref ref-type="bibr" rid="ref7">7</xref>]. However, fasting insulin, one of its components, is not a routine test, making it difficult to obtain in community and grassroots settings. Based on laboratory indicators and lifestyle characteristics that are correlated with the occurrence of IR and are easily accessible, it is crucial to explore more convenient ways to predict the previous probability of IR in individuals. This approach could guide more precise IR screening and has the potential for prevention and control within the large population of China.</p><p>Machine learning (ML), with its data-driven methods, has already shown good predictive value in health issues such as arteriosclerosis [<xref ref-type="bibr" rid="ref8">8</xref>], fatty liver [<xref ref-type="bibr" rid="ref9">9</xref>], diabetes [<xref ref-type="bibr" rid="ref10">10</xref>], and hypertension [<xref ref-type="bibr" rid="ref11">11</xref>] . Obesity, dyslipidemia, lack of exercise, and sedentary lifestyles are considered risk factors for metabolic homeostasis [<xref ref-type="bibr" rid="ref12">12</xref>]. By applying daily habits, basic information, and simple blood tests as features, we can build machine learning models in health check-up populations that are representative of the general population. The model of the ensemble learning algorithms based on decision trees, such as random forest (RF), Light Gradient Boosting Machine (LightGBM), Extreme Gradient Boosting (XGBoost), Gradient Boosting Machine (GBDT), and CatBoost, using multiple decision trees for predictions. They are capable of capturing complex nonlinear relationships, handling high-dimensional data, performing automatic feature selection, and mitigating the risk of overfitting through various mechanisms. In addition, these models offer strong scalability and are suitable for large-scale datasets, with most models having built-in overfitting prevention capabilities. These models can effectively predict IR and identify key predictive factors that are crucial for individual intervention. In addition, a retrospective cohort study can be used to determine the accuracy and practical value of these model results in distinguishing the onset of diabetes.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study Population and Data Sources</title><p>The data used in this study were sourced from the electronic medical records of the Health Management Center at Xiangya Third Hospital, Central South University. The dataset includes participants who underwent physical examinations and questionnaire surveys at the Health Management Center between January 2018 and August 2022. A total of 17,287 adults with normal fasting blood glucose (FBG) were included, while individuals with FBG &#x2265;6.1mmol/L or those with a history of abnormal glucose tolerance or diabetes were excluded.</p><p>The subsequent retrospective cohort consisted of individuals who completed their first health check-up at the Health Management Center of Xiangya Third Hospital between January 2017 and January 2019. These participants were followed for 5 years, with those diagnosed with diabetes at external hospitals or those who had completed &#x2265;2 times FBG tests at the hospital during the follow-up period being included. Participants were required to be aged 18 years or older and have FBG &#x003C;6.1mmol/L at the time of their first check-up. They also had to complete baseline assessments and surveys. Exclusion criteria included a history of abnormal glucose tolerance, diabetes, or gestational diabetes, as well as a history of tumors, pregnancy, or autoimmune diseases; and those who had used glucocorticoids or other relevant medications within the past month.</p><p>Using an IR prediction model, individuals in the cohort were classified as low-risk or high-risk based on their baseline data. Changes in FBG were then monitored. A FBG &#x2265;7 mmol/L within 5 years or a diagnosis of diabetes at an external hospital was considered a positive result. A negative result was defined as maintaining normal FBG levels without a diabetes diagnosis at an external hospital over the 5-year follow-up period. Furthermore, by matching the ID card numbers, we excluded the participants who repeatedly appeared in the training set and the test set. Ensure this cohort was the different from the dataset used for model development.</p></sec><sec id="s2-2"><title>Characteristics and Definitions</title><p>The dataset includes a total of 102 features, which encompass physical examination measurements such as age, height, weight, BMI, waist circumference (WC), systolic blood pressure (SBP), and diastolic blood pressure (DBP). Blood test indicators include FBG, liver function markers (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin [TBIL], direct bilirubin [DBIL], serum albumin [ALB], serum globulin [GLO], albumin/globulin ratio [A/G], total proteintotal [TP], bile acids [TBA]), kidney function markers (serum creatinine [Sr], blood urea nitrogen [BUN], uric acid [UA], and lipid profile markers (total cholesterol [TC], triglycerides (TG], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C]. In addition, information from questionnaires was collected, including past disease diagnoses, lifestyle factors (dietary preferences, smoking status, alcohol consumption, exercise habits, and work status), psychological status, sleep patterns, and health literacy related to basic medical knowledge. Insulin sensitivity was assessed using HOMA-IR=fasting glucose (mmol/L)&#x00D7;fasting insulin (&#x03BC;U/ml) / 22.5. A cut-off value of 2.69 was used, with a value &#x2265;2.69 considered indicative of IR status [<xref ref-type="bibr" rid="ref5">5</xref>].</p></sec><sec id="s2-3"><title>Data Processing and Statistical Analysis</title><p>We excluded features with more than 30% missing data. For features with less than 30% missing data, continuous variables were imputed using the mean, while categorical variables were imputed using the mode. Ultimately, 90 features and 16,411 samples were retained. The entire dataset was randomly split into a training set (13,128/16411, 80% samples) and a test set (3283/16411, 20% samples), with 2782 samples categorized as IR.</p><p>For statistical analysis, continuous data that conform to a normal distribution were reported as means (SDs), otherwise, were reported as quartiles. Chi-square tests were conducted on categorical variables to assess the significant association between categorical features and the dependent variable. <italic>P</italic>&#x003C;.05 was considered statistically significant.</p></sec><sec id="s2-4"><title>Feature Engineering</title><sec id="s2-4-1"><title>Resampling</title><p>In this study, 3 resampling techniques, namely random undersampling, synthetic minority oversampling technique (SMOTE) oversampling, and SMOTE-Tomek combined sampling were experimentally compared during the dataset preprocessing phase. It was found that random undersampling performed best in improving the prediction accuracy for the minority class. Therefore, random undersampling was applied to the training set, where a portion of the majority class samples were randomly removed to reduce the majority class sample size. This approach helped mitigate model bias toward the majority class and improved overall classification performance.</p></sec><sec id="s2-4-2"><title>Feature Processing and Algorithm Selection</title><p>To enhance model accuracy and efficiency, reduce computational costs, and avoid overfitting, feature selection was conducted. Before feature selection, Pearson correlation analysis was conducted for continuous features, while Kendall correlation analysis was used for discrete features. By examining the correlation matrix of the features, pairs of highly correlated features (with correlation coefficients &#x003E;0.6) were identified, and perform dimensionality reduction on these highly relevant features. A total of 5 machine learning algorithms, including RF, LightGBM, XGBoost, GBDT, and CatBoost were used to construct predictive models on the training dataset. The model demonstrating the best performance across various evaluation metrics was selected from the baseline models (CatBoost was chosen based on experimental results). The CatBoost model was then trained, and the importance scores for each feature were determined. Features were added to the model in descending order of importance until the AUC score stabilized at its highest value with a specific number of features. At this point, no further features were added, and the model was constructed using the selected features.</p></sec></sec><sec id="s2-5"><title>Parameter Optimization and Model Evaluation</title><p>In addition to addressing class imbalance through resampling techniques, the model parameters were adjusted to assign different weights to each class, thereby balancing the class distribution. For the RF, GBDT, and CatBoost models, the parameter class_weight = &#x201C;balanced&#x201D; was set, while for the LightGBM and XGBoost models, scale_pos_weight = &#x201C;ratio of majority and minority class&#x201D; was used. Bayesian optimization was used for parameter tuning. Bayesian optimization is a global optimization algorithm based on Bayesian inference, which iteratively updates the posterior distribution of the parameters to identify the optimal configuration and optimize the objective function. To evaluate the optimization effects and improve the model&#x2019;s generalization ability, 10-fold cross-validation was performed. The experiments were repeated 10 times, and metrics such as area under the receiver operating characteristic curve were averaged to assess model performance. In addition, model performance was evaluated using the <italic>F</italic><sub>1</sub>-score, accuracy, sensitivity, and specificity, while the receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to assess the model&#x2019;s discriminatory ability. The Kappa value was also computed to evaluate the predictive capability of the model.</p><p>This research used several Python libraries and frameworks for data processing, feature engineering, model building, and hyperparameter tuning. The main tools used in the study are Python (version 3.6.4), NumPy (version 1.18.5), Pandas (version 1.1.5), SciPy (version 1.5.2), scikit-learn (version 0.24.2), LightGBM (version 4.3.0) XGBoost (version 1.5.2), CatBoost (version 1.1.1), and bayes_opt (version 1.4.0).</p></sec><sec id="s2-6"><title>Feature Importance Ranking</title><p>Shapley Additive Explanations (SHAP) values are a method used to interpret machine learning model predictions. SHAP assigns a value to each feature, quantifying its contribution to the model&#x2019;s output. Positive SHAP values indicate that the feature has a beneficial impact on the prediction, while negative SHAP values suggest a detrimental effect. The absolute magnitude of a SHAP value reflects the extent of the feature&#x2019;s influence on the model&#x2019;s decision. In this study, we used SHAP (version 0.45.0) for explainable machine learning to enhance interpretability.</p></sec><sec id="s2-7"><title>Retrospective Cohort Validation of Model Application</title><p>Retrospective cohort data from a nondiabetic population were used as input to the aforementioned algorithms. The model outputs predicted the IR values for each participant, where a value of 1 was classified as high-risk IR and 0 as low-risk IR. Kaplan-Meier survival curves were used to conduct time-to-event analysis, comparing the 5-year diabetes incidence between the high-risk and low-risk IR groups. This approach further validated the model&#x2019;s ability to accurately distinguish the onset of diabetes based on predicted IR levels.</p></sec><sec id="s2-8"><title>Ethical Considerations</title><p>This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Xiangya Third Hospital, Central South University (approval no. 22206). All participants provided informed consent. The data were deidentified to ensure privacy protection.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Characteristics of the Study Population</title><p>The study flow chart is presented in <xref ref-type="fig" rid="figure1">Figure 1</xref>. A total of 16,411 nondiabetic individuals who underwent health screenings were included in this study, with an average age of 42.74 (SD 11.36) years. The sample comprised 8205 males and 8206 females. Overall, 17% of participants were diagnosed with IR, with a higher prevalence observed in males compared with females. In the IR group, levels of weight, WC, BMI, SBP, UA, ALT, AST, TG, and TC were significantly elevated compared with the non-IR group. Conversely, the average HDL-C level was significantly lower in the IR group (<italic>P</italic>&#x003C;.05). In addition, lifestyle factors such as diet, physical activity, and health literacy exhibited significant differences between the 2 groups (<xref ref-type="table" rid="table1">Tables 1</xref> and <xref ref-type="table" rid="table2">2</xref>).</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>Flow diagram of the study. The flow diagram of the study shows the entire research process, from data collection, preprocessing, model training and testing to final model evaluation and validation. AUC: area under the curve; GBDT: Gradient Boosting Machine; LightGBM: Light Gradient Boosting Machine; RF: random forest; SHAP: Shapley Additive Explanations; XGBoost: Extreme Gradient Boosting.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="medinform_v13i1e72238_fig01.png"/></fig><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Continuous characteristics of participants, including age, height, weight, waist circumference, BMI, blood pressure, and blood biochemical indicators, and a comparison of the means and SDs between the insulin resistance and non&#x2013;insulin resistance groups, along with the corresponding <italic>P</italic> values to evaluate the association of each characteristic with insulin resistance.</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">All (n=16,411), mean (SD)</td><td align="left" valign="bottom">IR<sup><xref ref-type="table-fn" rid="table1fn1">a</xref></sup> (HOMA<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup>-IR &#x003C;2.69; n=13,629), mean (SD)</td><td align="left" valign="bottom">Non-IR (HOMA-IR &#x2265;2.5; n=2782), mean (SD)</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">Age (years)</td><td align="left" valign="top">42.74 (11.36)</td><td align="left" valign="top">42.84 (11.37)</td><td align="left" valign="top">42.23 (11.30)</td><td align="left" valign="top">.01</td></tr><tr><td align="left" valign="top">Height (cm)</td><td align="left" valign="top">163.50 (8.00)</td><td align="left" valign="top">163.14 (7.93)</td><td align="left" valign="top">165.29 (8.21)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Weight (kg)</td><td align="left" valign="top">63.80 (11.70)</td><td align="left" valign="top">62.21 (11.10)</td><td align="left" valign="top">71.48 (11.59)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">WC (cm)<sup><xref ref-type="table-fn" rid="table1fn3">c</xref></sup></td><td align="left" valign="top">81.30 (10.40)</td><td align="left" valign="top">79.82 (9.81)</td><td align="left" valign="top">88.53 (9.67)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">BMI (kg/m<sup>2</sup>)<sup><xref ref-type="table-fn" rid="table1fn4">d</xref></sup></td><td align="left" valign="top">23.85 (3.37)</td><td align="left" valign="top">23.30 (3.07)</td><td align="left" valign="top">26.54 (3.48)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">SBP (mmHg)<sup><xref ref-type="table-fn" rid="table1fn5">e</xref></sup></td><td align="left" valign="top">120.39 (14.83)</td><td align="left" valign="top">119.49 (14.7)</td><td align="left" valign="top">124.75 (14.62)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">DBP (mmHg)<sup><xref ref-type="table-fn" rid="table1fn6">f</xref></sup></td><td align="left" valign="top">73.80 (10.80)</td><td align="left" valign="top">73.08 (10.71)</td><td align="left" valign="top">77.02 (11.04)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">BUN (mmol/L)<sup><xref ref-type="table-fn" rid="table1fn7">g</xref></sup></td><td align="left" valign="top">4.72 (1.22)</td><td align="left" valign="top">4.71 (1.23)</td><td align="left" valign="top">4.79 (1.19)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Sr (umol/L)<sup><xref ref-type="table-fn" rid="table1fn8">h</xref></sup></td><td align="left" valign="top">70.31 (18.15)</td><td align="left" valign="top">69.99 (18.52)</td><td align="left" valign="top">71.85 (16.12)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">UA (umol/L)<sup><xref ref-type="table-fn" rid="table1fn9">i</xref></sup></td><td align="left" valign="top">339.53 (92.01)</td><td align="left" valign="top">331.13 (89.53)</td><td align="left" valign="top">380.70 (92.91)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">TBA (umol/L)<sup><xref ref-type="table-fn" rid="table1fn10">j</xref></sup></td><td align="left" valign="top">4.22 (4.80)</td><td align="left" valign="top">4.18 (4.82)</td><td align="left" valign="top">4.44 (4.69)</td><td align="left" valign="top">.01</td></tr><tr><td align="left" valign="top">ALT (u/L)<sup><xref ref-type="table-fn" rid="table1fn11">k</xref></sup></td><td align="left" valign="top">26.46 (25.62)</td><td align="left" valign="top">23.30 (24.73)</td><td align="left" valign="top">36.09 (27.21)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">AST (u/L)<sup><xref ref-type="table-fn" rid="table1fn12">l</xref></sup></td><td align="left" valign="top">24.89 (18.88)</td><td align="left" valign="top">24.50 (20.07)</td><td align="left" valign="top">26.83 (11.17)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">ALB (g/L)<sup><xref ref-type="table-fn" rid="table1fn13">m</xref></sup></td><td align="left" valign="top">46.62 (2.91)</td><td align="left" valign="top">46.63 (2.91)</td><td align="left" valign="top">46.60 (2.93)</td><td align="left" valign="top">.56</td></tr><tr><td align="left" valign="top">GLO (g/L)<sup><xref ref-type="table-fn" rid="table1fn14">n</xref></sup></td><td align="left" valign="top">27.09 (3.68)</td><td align="left" valign="top">26.93 (3.65)</td><td align="left" valign="top">27.88 (3.71)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">A/G<sup><xref ref-type="table-fn" rid="table1fn15">o</xref></sup></td><td align="left" valign="top">1.73 (0.24)</td><td align="left" valign="top">1.74 (0.24)</td><td align="left" valign="top">1.70 (0.25)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">TP (g/L)<sup><xref ref-type="table-fn" rid="table1fn16">p</xref></sup></td><td align="left" valign="top">73.72 (4.22)</td><td align="left" valign="top">73.56 (4.19)</td><td align="left" valign="top">74.47 (4.30)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">DBIL (umol/L)<sup><xref ref-type="table-fn" rid="table1fn17">q</xref></sup></td><td align="left" valign="top">3.78 (1.34)</td><td align="left" valign="top">3.83 (1.35)</td><td align="left" valign="top">3.54 (1.26)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">TBIL (umol/L)<sup><xref ref-type="table-fn" rid="table1fn18">r</xref></sup></td><td align="left" valign="top">13.02 (5.06)</td><td align="left" valign="top">13.21 (5.11)</td><td align="left" valign="top">12.05 (4.70)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">FBG (mmol/L)<sup><xref ref-type="table-fn" rid="table1fn19">s</xref></sup></td><td align="left" valign="top">5.24 (0.42)</td><td align="left" valign="top">5.20 (0.42)</td><td align="left" valign="top">5.45 (0.40)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">TG (mmol/L)<sup><xref ref-type="table-fn" rid="table1fn20">t</xref></sup></td><td align="left" valign="top">1.70 (1.53)</td><td align="left" valign="top">1.55 (1.36)</td><td align="left" valign="top">2.44 (2.01)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">TC (mmol/L)<sup><xref ref-type="table-fn" rid="table1fn21">u</xref></sup></td><td align="left" valign="top">5.01 (0.94)</td><td align="left" valign="top">4.98 (0.93)</td><td align="left" valign="top">5.16 (1.00)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">HDL-C (mmol/L)<sup><xref ref-type="table-fn" rid="table1fn22">v</xref></sup></td><td align="left" valign="top">1.33 (0.30)</td><td align="left" valign="top">1.36 (0.29)</td><td align="left" valign="top">1.17 (0.24)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">LDL-C (mmol/L)<sup><xref ref-type="table-fn" rid="table1fn23">w</xref></sup></td><td align="left" valign="top">2.89 (0.79)</td><td align="left" valign="top">2.88 (0.78)</td><td align="left" valign="top">2.93 (0.84)</td><td align="left" valign="top">&#x003C;.001</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup> IR: Insulin resistance.</p></fn><fn id="table1fn2"><p><sup>b</sup>HOMA: Homeostasis Model Assessment.</p></fn><fn id="table1fn3"><p><sup>c</sup> WC: waist circumference.</p></fn><fn id="table1fn4"><p><sup>d</sup> BMI: body mass index.</p></fn><fn id="table1fn5"><p><sup>e</sup> SBP: systolic blood pressure.</p></fn><fn id="table1fn6"><p><sup>f</sup> DBP: diastolic blood pressure.</p></fn><fn id="table1fn7"><p><sup>g</sup> BUN: blood urea nitrogen.</p></fn><fn id="table1fn8"><p><sup>h</sup> Sr: serum creatinine.</p></fn><fn id="table1fn9"><p><sup>i</sup> UA: uric acid.</p></fn><fn id="table1fn10"><p><sup>j</sup> TBA: total bile acids.</p></fn><fn id="table1fn11"><p><sup>k</sup> ALT: alanine aminotransferase.</p></fn><fn id="table1fn12"><p><sup>l</sup> AST: aspartate aminotransferase.</p></fn><fn id="table1fn13"><p><sup>m</sup> ALB: serum albumin.</p></fn><fn id="table1fn14"><p><sup>n</sup> GLO: serum globulin.</p></fn><fn id="table1fn15"><p><sup>o</sup> A/G: albumin/globulin ratio.</p></fn><fn id="table1fn16"><p><sup>p</sup> TP: total protein.</p></fn><fn id="table1fn17"><p><sup>q</sup> DBIL: direct bilirubin.</p></fn><fn id="table1fn18"><p><sup>r</sup> TBIL: total bilirubin.</p></fn><fn id="table1fn19"><p><sup>s</sup> FBG: fasting blood glucose.</p></fn><fn id="table1fn20"><p><sup>t</sup> TG: triglycerides.</p></fn><fn id="table1fn21"><p><sup>u</sup> TC: total cholesterol.</p></fn><fn id="table1fn22"><p><sup>v</sup> HDL-C: high-density lipoprotein cholesterol.</p></fn><fn id="table1fn23"><p><sup>w</sup> LDL-C: low-density lipoprotein cholesterol.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" position="float"><label>Table 2.</label><caption><p>Questionnaire characteristics of participants, including dietary habits, exercise, lifestyle, psychological status, and health literacy, and an assessment of the association of each characteristic with insulin resistance using the chi-square test, listing the chi-square values and <italic>P</italic> values.</p></caption><table id="table2" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Type and feature</td><td align="left" valign="bottom">Chi-square (<italic>df</italic>) value</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">Diet</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Dietary preference</td><td align="left" valign="top">137.86 (13)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Daily meat intake</td><td align="left" valign="top">123.43 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Fruit consumption</td><td align="left" valign="top">29.81 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Coffee consumption</td><td align="left" valign="top">21.22 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Nighttime snacking</td><td align="left" valign="top">54.97 (2)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Social dining</td><td align="left" valign="top">90.56 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Legume and soy product consumption</td><td align="left" valign="top">13.40 (4)</td><td align="left" valign="top">.01</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Fish or seafood consumption</td><td align="left" valign="top">7.24 (4)</td><td align="left" valign="top">.12</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sugary drink consumption</td><td align="left" valign="top">106.32 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Dietary taste</td><td align="left" valign="top">125.78 (2)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Fat meat consumption</td><td align="left" valign="top">88.97 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Animal organ consumption</td><td align="left" valign="top">25.31 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Staple food structure</td><td align="left" valign="top">33.95 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Binge eating</td><td align="left" valign="top">73.63 (1)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Daily vegetable intake</td><td align="left" valign="top">23.77 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Milk consumption</td><td align="left" valign="top">13.20 (4)</td><td align="left" valign="top">.01</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Egg consumption</td><td align="left" valign="top">1.83 (3)</td><td align="left" valign="top">.61</td></tr><tr><td align="left" valign="top">Exercise</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Physical exercise</td><td align="left" valign="top">56.60 (2)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Weekly exercise frequency</td><td align="left" valign="top">59.24 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Exercise duration per session</td><td align="left" valign="top">54.73 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Exercise type</td><td align="left" valign="top">122.97 (31)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Years of consistent exercise</td><td align="left" valign="top">60.50 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Lifestyle</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Alcohol consumption</td><td align="left" valign="top">29.25 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Alcohol frequency per week</td><td align="left" valign="top">25.38 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Years of alcohol use</td><td align="left" valign="top">36.00 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Alcohol quantity per session</td><td align="left" valign="top">57.59 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Type of alcohol</td><td align="left" valign="top">13.95 (6)</td><td align="left" valign="top">.03</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Time since quitting drinking</td><td align="left" valign="top">6.65 (4)</td><td align="left" valign="top">.16</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Work physical demands</td><td align="left" valign="top">95.25 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Workdays per week</td><td align="left" valign="top">3.85 (3)</td><td align="left" valign="top">.28</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Working hours per week</td><td align="left" valign="top">3.36 (4)</td><td align="left" valign="top">.50</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Smoking habits</td><td align="left" valign="top">42.55 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Cigarettes per day</td><td align="left" valign="top">38.48 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Years of smoking</td><td align="left" valign="top">56.12 (4)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Exposure to Harmful Substances</td><td align="left" valign="top">47.16 (18)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sedentary time outside work</td><td align="left" valign="top">36.27 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Regular meals</td><td align="left" valign="top">9.12 (3)</td><td align="left" valign="top">.03</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sleep quality</td><td align="left" valign="top">1.01 (2)</td><td align="left" valign="top">.60</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Reasons for sleep disturbance</td><td align="left" valign="top">22.03 (12)</td><td align="left" valign="top">.04</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sleep duration</td><td align="left" valign="top">3.52 (3)</td><td align="left" valign="top">.32</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Main symptoms of sleep disturbance</td><td align="left" valign="top">15.448 (12)</td><td align="left" valign="top">.22</td></tr><tr><td align="left" valign="top">Psychology</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Depression</td><td align="left" valign="top">0.10 (2)</td><td align="left" valign="top">.95</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Difficulty concentrating</td><td align="left" valign="top">8.45 (3)</td><td align="left" valign="top">.04</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Increased anxiety</td><td align="left" valign="top">1.57 (2)</td><td align="left" valign="top">.46</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Burnout</td><td align="left" valign="top">1.89 (2)</td><td align="left" valign="top">.39</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Depressed</td><td align="left" valign="top">3.19 (3)</td><td align="left" valign="top">.36</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Anxious</td><td align="left" valign="top">0.18 (2)</td><td align="left" valign="top">.91</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Anxiety and restlessness</td><td align="left" valign="top">0.56 (2)</td><td align="left" valign="top">.76</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Irritable</td><td align="left" valign="top">0.76 (2)</td><td align="left" valign="top">.68</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Impatience</td><td align="left" valign="top">2.07 (2)</td><td align="left" valign="top">.36</td></tr><tr><td align="left" valign="top">Health literacy</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal WC<sup><xref ref-type="table-fn" rid="table2fn1">a</xref></sup></td><td align="left" valign="top">25.37 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Active medical knowledge acquisition</td><td align="left" valign="top">22.63 (2)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Self-Monitoring of blood pressure and heart rate</td><td align="left" valign="top">20.81 (2)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal BP<sup><xref ref-type="table-fn" rid="table2fn2">b</xref></sup></td><td align="left" valign="top">7.82 (1)</td><td align="left" valign="top">.01</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal BMI</td><td align="left" valign="top">6.71 (1)</td><td align="left" valign="top">.01</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal FBG<sup><xref ref-type="table-fn" rid="table2fn3">c</xref></sup></td><td align="left" valign="top">1.71 (1)</td><td align="left" valign="top">.19</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal T<sup><xref ref-type="table-fn" rid="table2fn4">d</xref></sup></td><td align="left" valign="top">1.02 (1)</td><td align="left" valign="top">.31</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal HR<sup><xref ref-type="table-fn" rid="table2fn5">e</xref></sup></td><td align="left" valign="top">1.07 (1)</td><td align="left" valign="top">.30</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal TG<sup><xref ref-type="table-fn" rid="table2fn6">f</xref></sup></td><td align="left" valign="top">0.72 (1)</td><td align="left" valign="top">.39</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal TC<sup><xref ref-type="table-fn" rid="table2fn7">g</xref></sup></td><td align="left" valign="top">2.66 (1)</td><td align="left" valign="top">.10</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Normal Salt intake</td><td align="left" valign="top">78.68</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>History of hypertension</td><td align="left" valign="top">127.39 (2)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Family history medicine</td><td align="left" valign="top">791.80 (509)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Observe urination and defecation</td><td align="left" valign="top">13.10 (2)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Bask</td><td align="left" valign="top">13.10 (3)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Seat belt usage</td><td align="left" valign="top">7.09 (2)</td><td align="left" valign="top">.03</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Carrying emergency medication</td><td align="left" valign="top">3.35 (2)</td><td align="left" valign="top">.19</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Health check-up interval</td><td align="left" valign="top">12.46 (5)</td><td align="left" valign="top">.03</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Personal history disease</td><td align="left" valign="top">1.25 (1)</td><td align="left" valign="top">.26</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>FH: DM<sup><xref ref-type="table-fn" rid="table2fn8">h</xref></sup></td><td align="left" valign="top">4.00 (1)</td><td align="left" valign="top">.05</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sex</td><td align="left" valign="top">151.26 (1)</td><td align="left" valign="top">&#x003C;.001</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p><sup>a</sup>WC: waist circumference</p></fn><fn id="table2fn2"><p><sup>b</sup>BP: blood pressure</p></fn><fn id="table2fn3"><p><sup>c</sup>FBG: fasting blood glucose</p></fn><fn id="table2fn4"><p><sup>d</sup>T: temperature</p></fn><fn id="table2fn5"><p><sup>e</sup>HR: heart rate</p></fn><fn id="table2fn6"><p><sup>f</sup>TG: triglycerides</p></fn><fn id="table2fn7"><p><sup>g</sup>TC: total cholesterol</p></fn><fn id="table2fn8"><p><sup>h</sup>FH: DM: family history of diabetes.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Feature Engineering</title><p>In the training set, random undersampling was applied to the majority class. Among the &#x201C;physiological features,&#x201D; 4 highly correlated features: &#x201C;BMI,&#x201D; &#x201C;height,&#x201D; &#x201C;weight,&#x201D; and &#x201C;WC&#x201D; were subjected to dimensionality reduction, with &#x201C;BMI&#x201D; retained. Similarly, for the 2 highly correlated features &#x201C;SBP&#x201D; and &#x201C;DBP,&#x201D; only &#x201C;SBP&#x201D; was retained.</p><p>Feature importance scores were computed for 55 lifestyle-related questionnaire features using the CatBoost algorithm. These features were ranked from high to low based on their importance scores and then sequentially input into the CatBoost model. After each addition, the model&#x2019;s AUC score on the test set was recorded. As shown in <xref ref-type="fig" rid="figure2">Figure 2</xref>, the AUC score dropped significantly after adding 35 features, leading to the exclusion of 21 noncontributory questionnaire features. The 34 retained features, which showed significant contributions, include BMI, SBP, age, sex, family history medicine, exercise type, years of consistent exercise, exercise duration per session, weekly exercise frequency, dietary preferences, staple food structure, dietary taste, sleep duration, reasons for sleep disturbance, exposure to harmful substances, work physical demands, sedentary duration outside of work, consumption frequency of fruits, milk, meat, coffee, legume and soy products, sugary drink and fatty meats, daily vegetable intake, health check-up interval , self-monitoring of blood pressure and heart rate, observe urination and defecation, carrying emergency medications, regular meals, seat belt usage, bask, and awareness of normal salt intake and hazard ratio (HR).</p><p>In addition, the addition of 17 biochemical markers, BUN, Cr, UA, TC, TG, HDL-C, LDL-C, FBG, ALT, AST, TBIL, DBIL, TSP, ALB, GLO, A/G ratio, and TBA further improved the model&#x2019;s accuracy, sensitivity, and specificity. Thus, the final feature selection for the model included the 34 lifestyle-related questionnaire features and 17 biochemical markers.</p><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>The model&#x2019;s area under the curve (AUC) score on the test set. This figure shows how the AUC score on the test set changes with the number of features included in the model. After adding 34 features, the AUC score drops significantly, indicating that these additional features no longer contribute to model performance improvement.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="medinform_v13i1e72238_fig02.png"/></fig></sec><sec id="s3-3"><title>Model Performance Evaluation and Feature Importance Ranking</title><p>Based on the 51 selected features (34 questionnaire features and 17 biochemical markers), 5 ML algorithms were applied, RF, LightGBM, XGBoost, GBDT, and CatBoost to build and evaluate models using both the training and testing datasets. The performance metrics of the 5 ML models are summarized in <xref ref-type="table" rid="table3">Table 3</xref>. The LightGBM model demonstrated the best performance across all metrics, including accuracy (0.7542), sensitivity (0.6639), specificity (0.7642), <italic>F</italic><sub>1</sub>-score (0.6748), and &#x03BA; (0.3741). Although the AUC (0.8456) of the LightGBM model was slightly lower than that of CatBoost, LightGBM was determined to be the best model overall for predicting IR. The ROC curve for the best-performing LightGBM model is shown in <xref ref-type="fig" rid="figure3">Figure 3</xref>.</p><p>SHAP values were used to rank feature importance in the LightGBM model, as shown in <xref ref-type="fig" rid="figure4">Figure 4A</xref>. The top 10 features influencing IR were: BMI, FBG, HDL-C, TG, Cr, ALT, sex, TBIL, age, and A/G ratio. <xref ref-type="fig" rid="figure4">Figure 4B</xref> provides a visual representation of the SHAP values for the top 10 features, where BMI, FBG, TG, ALT, and sex were positively correlated with IR, while HDL-C, Cr, TBIL, age, and A/G ratio were negatively correlated with IR.</p><table-wrap id="t3" position="float"><label>Table 3.</label><caption><p>Performances of the 5 machine learning models using 51 selected features for participants.</p></caption><table id="table3" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Model</td><td align="left" valign="bottom">Accuracy_train</td><td align="left" valign="bottom">Accuracy_test</td><td align="left" valign="bottom">Sensitivity</td><td align="left" valign="bottom">Specificity</td><td align="left" valign="bottom"><italic>F</italic><sub>1</sub>-score</td><td align="left" valign="bottom">AUC_train</td><td align="left" valign="bottom">AUC_test</td><td align="left" valign="bottom">&#x03BA; value</td></tr></thead><tbody><tr><td align="left" valign="top">RF<sup><xref ref-type="table-fn" rid="table3fn1">a</xref></sup></td><td align="char" char="." valign="top">0.8807</td><td align="char" char="." valign="top">0.7344</td><td align="char" char="." valign="top">0.6522</td><td align="char" char="." valign="top">0.7516</td><td align="char" char="." valign="top">0.6571</td><td align="char" char="." valign="top">0.9552</td><td align="char" char="." valign="top">0.8354</td><td align="char" char="." valign="top">0.3451</td></tr><tr><td align="left" valign="top">LightGBM<sup><xref ref-type="table-fn" rid="table3fn2">b</xref></sup></td><td align="char" char="." valign="top">0.8503</td><td align="char" char="." valign="top">0.7542</td><td align="char" char="." valign="top">0.6639</td><td align="char" char="." valign="top">0.7642</td><td align="char" char="." valign="top">0.6748</td><td align="char" char="." valign="top">0.9285</td><td align="char" char="." valign="top">0.8456</td><td align="char" char="." valign="top">0.3741</td></tr><tr><td align="left" valign="top">XGBoost<sup><xref ref-type="table-fn" rid="table3fn3">c</xref></sup></td><td align="char" char="." valign="top">0.9689</td><td align="char" char="." valign="top">0.7460</td><td align="char" char="." valign="top">0.6575</td><td align="char" char="." valign="top">0.7556</td><td align="char" char="." valign="top">0.6662</td><td align="char" char="." valign="top">0.9966</td><td align="char" char="." valign="top">0.8375</td><td align="char" char="." valign="top">0.3588</td></tr><tr><td align="left" valign="top">GBDT<sup><xref ref-type="table-fn" rid="table3fn4">d</xref></sup></td><td align="char" char="." valign="top">0.9237</td><td align="char" char="." valign="top">0.7505</td><td align="char" char="." valign="top">0.6608</td><td align="char" char="." valign="top">0.7598</td><td align="char" char="." valign="top">0.6708</td><td align="char" char="." valign="top">0.9799</td><td align="char" char="." valign="top">0.8372</td><td align="char" char="." valign="top">0.3668</td></tr><tr><td align="left" valign="top">CatBoost</td><td align="char" char="." valign="top">0.8632</td><td align="char" char="." valign="top">0.7493</td><td align="char" char="." valign="top">0.6594</td><td align="char" char="." valign="top">0.7576</td><td align="char" char="." valign="top">0.6692</td><td align="char" char="." valign="top">0.9445</td><td align="char" char="." valign="top">0.8471</td><td align="char" char="." valign="top">0.3637</td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><p><sup>a</sup>RF: random forest.</p></fn><fn id="table3fn2"><p><sup>b</sup>LightGBM: Light Gradient Boosting Machine.</p></fn><fn id="table3fn3"><p><sup>c</sup>XGBoost: Extreme Gradient Boosting.</p></fn><fn id="table3fn4"><p><sup>d</sup>GBDT: Gradient Boosting Machine.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="figure3"><label>Figure 3.</label><caption><p>Prediction of insulin resistance in patients with insulin resistance by Light Gradient Boosting Machine, ROC in test set. The area under the curve is 0.8456, indicating that the model has good discriminant ability. ROC: receiver operating characteristic.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="medinform_v13i1e72238_fig03.png"/></fig><fig position="float" id="figure4"><label>Figure 4.</label><caption><p>Detailed feature importance. (A) Feature importance by Light Gradient Boosting Machine. It shows the importance ranking of various features in the Light Gradient Boosting Machine model. The vertical coordinate (y-axis) shows the top 20 features and (B) shows the explanation of each feature impact on insulin resistance in the prediction model by the Shapley Additive Explanations (SHAP) values in the Light Gradient Boosting Machine algorithm. A/G: albumin/globulin ratio; ALT: alanine aminotransferase; Cr: creatinine; FBG: fasting blood glucose; HDL-C: high-density lipoprotein cholesterol; SG: serum glutamic; TBA: bile acids; TBIL: total bilirubin; TG: triglycerides; UA: uric acid.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="medinform_v13i1e72238_fig04.png"/></fig></sec><sec id="s3-4"><title>Retrospective Cohort for Validation and Clinical Significance Assessment</title><p>The retrospective cohort dataset was used to validate the differential occurrence of diabetes in populations stratified by the model. A total of 20,369 nondiabetic participants were continuously monitored (5101 individuals classified as IR high risk by LightGBM and 15,268 individuals classified as IR low risk), with the incidence of diabetes compared from baseline to 5 years. Out of 5101 high-risk IR participants, 235 (4.6%) developed diabetes, while 137 (0.9%) of 15,268 low-risk IR participants did. This resulted in a HR of 5.1, indicating a significantly higher risk for the IR high risk group compared with the IR Low Risk group. <xref ref-type="fig" rid="figure5">Figure 5A</xref> clearly illustrates the relationship between the cumulative incidence of diabetes in the high- and low-risk insulin resistance groups. The high-risk group exhibited a significantly higher cumulative incidence of diabetes compared with the low-risk group, particularly after the second year of follow-up, when the rate of increase accelerated. This suggests that individuals in the high-risk group have a higher likelihood of developing diabetes, and the cumulative effect of this risk becomes more pronounced over time.</p><p>The curve for the low-risk group starts at 1 (indicating that 100% of individuals were free of diabetes) and gradually declines over time, although the decrease is relatively small. In contrast, the high-risk group shows a much more rapid decline, especially after the second year, with a more noticeable downward trend (<xref ref-type="fig" rid="figure5">Figure 5B</xref>). The line chart depicting the diabetes incidence rates across different IR risk groups (<xref ref-type="fig" rid="figure5">Figure 5C</xref>) shows that the growth rate of incidence in the high-risk group is significantly higher than in the low-risk group. The incidence in the high-risk group rises sharply after the second year, reaching its peak by the fifth year. These findings suggest that individuals with high insulin resistance are more likely to develop diabetes within a shorter time frame.</p><fig position="float" id="figure5"><label>Figure 5.</label><caption><p>Clinical implication (incidence of diabetes) predicted by Light Gradient Boosting Machine algorithm from a retrospective cohort by the health management center. (A) Kaplan&#x2013;Meier curve of cumulative incidence of diabetes in different states of insulin resistance. The high-risk insulin resistance group has a significantly higher cumulative incidence of diabetes than the low-risk insulin resistance group. (B) Kaplan&#x2013;Meier curve of nonincidence of diabetes in different states of insulin resistance. The low-risk insulin resistance group has a significantly higher probability of not developing diabetes than the high-risk insulin resistance group. (C) Incidence of diabetes in different states of insulin resistance. The incidence in the high-risk insulin resistance group is significantly higher than that in the low-risk insulin resistance group, with a sharp increase after the second year.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="medinform_v13i1e72238_fig05.png"/></fig></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>This study applied multiple machine learning methods using a health check-up database from southern China. Based on questionnaire data and easily accessible, low-cost laboratory measurements, a highly effective predictive model for IR was developed in a population with normal FBG. This ensures that the data required for model implementation is readily available, without the need for additional, expensive diagnostic procedures. This model holds significant value for precision screening of IR and for targeting interventions aimed at managing individual risk factors associated with IR. Compared with other models, LightGBM demonstrated a clear overall advantage in terms of its parameters. LightGBM is a gradient boosting framework that uses decision tree-based learning algorithms. It offers several benefits, including faster training efficiency, lower memory usage, and higher accuracy. In addition, it supports parallel learning and is capable of handling large-scale datasets [<xref ref-type="bibr" rid="ref13">13</xref>].</p></sec><sec id="s4-2"><title>Comparison With Previous Work</title><p>The previous studies have developed insulin resistance prediction models targeting different ethnic groups and populations, which proves that researchers recognize the necessity of conducting IR prediction. Tsai integrated the National Health and Nutrition Examination Survey public database in the United States and the MAJOR database in Taiwan, China, and established the HOMA-IR ML (XGBoost) prediction model for adults in the two regions. The AUC reached 0.87, the important feature spectrum revealed by SHAP analysis was similar to our results, confirming the determinative roles of factors such as BMI, FBG,TG, HDL-C, and sex [<xref ref-type="bibr" rid="ref14">14</xref>]. Before this, the team also developed an IR model using samples from 1,229 chronic kidney disease patients sourced from the National Health and Nutrition Examination Survey database. The model included various nutritional and micronutrient indicators, and the overall evaluation metric showed that the XGBoost model achieved an AUC of 0.78 [<xref ref-type="bibr" rid="ref15">15</xref>]. Zhang et al [<xref ref-type="bibr" rid="ref16">16</xref>] developed a LightGBM model for IR in a cohort of nearly 10,000 adults aged 40 years or older from certain communities in Hubei, China, with an ROC score of 0.794. The most significant features included FBG, BMI, WC, TG, and sex. In a South Korean study involving 8842 residents, in addition to measurement and laboratory indicators, high-cost, high-quality features such as genetic risk scores, food frequency questionnaires, and nutrients were included, the best-performing model, XGBoost, achieved an AUC of 0.86 [<xref ref-type="bibr" rid="ref17">17</xref>]. However, these studies either use expensive features or fail to address multicollinearity issues between features. For example, physiological knowledge and typical data support a strong correlation between BMI and waist circumference [<xref ref-type="bibr" rid="ref18">18</xref>], but these studies did not account for multicollinearity, which could lead to overfitting.</p><p>In our preliminary model, using only low-cost questionnaire features did not yield the expected results. However, when laboratory indicators of liver function and blood lipids were added, the performance improved significantly. Both feature importance rankings based on LightGBM and SHAP value calculations showed that BMI, FBG, HDL-C, and TG were among the top 4 most important features. In fact, a 2003 consensus from the American College of Clinical Endocrinology [<xref ref-type="bibr" rid="ref19">19</xref>] formally defined IR syndrome as a multisystem disease centered around IR, with key elements including IR or hyperinsulinemia, with or without related cardiovascular-endocrine metabolic abnormalities. These elements include overweight BMI, abnormal glucose tolerance, hypertension, elevated TG, or reduced HDL-C, based on the established epidemiological correlation between IR and these indicators [<xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref>]. From a pathophysiological perspective, IR and these metabolic indicators have an explainable causal relationship. For example, adipokines secreted by adipose tissue, such as adiponectin [<xref ref-type="bibr" rid="ref22">22</xref>], tumor necrosis factor alpha [<xref ref-type="bibr" rid="ref23">23</xref>] can modulate insulin sensitivity through the insulin signaling pathway. In addition, hydrolysis products of elevated triglycerides, such as free fatty acids, can induce insulin resistance by inhibiting insulin signal transduction and reducing the number of insulin receptors on target cells [<xref ref-type="bibr" rid="ref24">24</xref>]. Low HDL-C improves insulin resistance through reverse cholesterol transport and anti-inflammatory effects [<xref ref-type="bibr" rid="ref25">25</xref>]. We also found that liver function indicators, such as ALT, bilirubin, and the A/G ratio, play a significant role in IR prediction, with fatty liver being closely linked to IR [<xref ref-type="bibr" rid="ref26">26</xref>]. These 3 abnormal indicators are common in individuals with fatty liver disease [<xref ref-type="bibr" rid="ref27">27</xref>], which may indirectly reflect IR. In addition, kidney function indicators showed correlations, which could be related to factors such as physical inactivity, chronic inflammation, oxidative stress, vitamin deficiencies, adipose factor imbalances, and changes in the gut microbiota in populations with kidney damage [<xref ref-type="bibr" rid="ref28">28</xref>]. Finally, we applied the best LightGBM model results to baseline IR stratification in a retrospective cohort, further validating the significant impact of IR prediction on diabetes incidence. This aims to clarify the practical value of such models. By comparing the incidence of diabetes in low-risk and high-risk IR groups, we observed that individuals at high risk for IR were more likely to develop diabetes in a shorter period, confirming the model&#x2019;s value in assessing blood glucose metabolism.</p></sec><sec id="s4-3"><title>Limitations and Future Directions</title><p>Despite the promising results in IR prediction, our study has several limitations. First, the data source is relatively limited in terms of geographical diversity. Our data came from a health check-up database from the Han Chinese population in Hunan Province in Central Southern China, which may impact the generalizability of the model to other regions or ethnic groups. Future studies could address this by incorporating data from different regions and ethnic populations to further validate the model&#x2019;s generalizability. We would try to develop these ML models into user-friendly web pages or applications that are accessible to the general public and primary care providers, getting more input information and feedback to optimize our models, which is virtually a significant advantage of ML. Second, we tested the clinical implications of this trained model with a retrospective cohort, and have not yet explored the predictive efficiency of the model in prospective research, and we plan to perform it in a follow-up study in the near future. Third, the diagnosis of diabetes in the cohort was based only on the results of FBG, rather than oral glucose tolerance test or combined with postprandial blood glucose or glycated hemoglobin. However, we hope to base diagnoses on the latter as well in further research in the near future. Finally, although 5 ML algorithms were used in this study, there may be other algorithms with better performance that are currently available or soon to be developed. It would be necessary for us to further iterate models with more promising algorithms to improve the predictive performance of the models in the future.</p></sec><sec id="s4-4"><title>Conclusions</title><p>In conclusion, the ML models using the LightGBM algorithm are efficient in predicting IR status in nondiabetic individuals. By leveraging low-cost laboratory indicators and questionnaire data, the model can accurately assess the current IR status in individuals with normal blood glucose levels, helping identify those at high risk of progressing to diabetes within large-scale populations.</p></sec></sec></body><back><ack><p>The authors thank all the staff, and participants of the Hunan University Of Technology and Business for their contributions to the research. This work was supported in part by the Hunan Natural Science Foundation (grant 2025JJ90208), the Chinese Cardiovascular Association-ASCVD fund (grant 2023-CCA-ASCVD-018), and the Project of State Key Clinical Department (grant Z2023058).</p></ack><notes><sec><title>Data Availability</title><p>The datasets generated or analyzed during this study are not publicly available due to privacy restrictions but are available from the corresponding author on reasonable request.</p></sec></notes><fn-group><fn fn-type="con"><p>RM conceived the study. TP and RM wrote the initial draft. TP and RM contributed equally to this work and are considered co&#x2013;first authors. JC and Y Li reviewed, commented on and revised further drafts. JC, and Y Li are considered co&#x2013;correspondence authors. Data analysis was conducted by Y Lin with the help of HX and DF. JR, JW, and RM provided financial support. All authors had full access to the data in the study and were responsible for the decision to submit for publication.</p><p>Author Y Li is the co-corresponding author of this paper, affilited with School of Mathematics and Statistics, Hunan University of Technology and Business, and can be reached at 2153813825@qq.com.</p></fn><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">A/G</term><def><p>albumin/globulin ratio</p></def></def-item><def-item><term id="abb2">ALB</term><def><p>serum albumin</p></def></def-item><def-item><term id="abb3">ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term id="abb4">AST</term><def><p>aspartate aminotransferase</p></def></def-item><def-item><term id="abb5">AUC</term><def><p>area under the curve</p></def></def-item><def-item><term id="abb6">BUN</term><def><p>blood urea nitrogen</p></def></def-item><def-item><term id="abb7">DBIL</term><def><p>direct bilirubin</p></def></def-item><def-item><term id="abb8">DBP</term><def><p>diastolic blood pressure</p></def></def-item><def-item><term id="abb9">FBG</term><def><p>fasting blood glucose</p></def></def-item><def-item><term id="abb10">GBDT</term><def><p>Gradient Boosting Machine</p></def></def-item><def-item><term id="abb11">GLO</term><def><p>serum globulin</p></def></def-item><def-item><term id="abb12">HDL-C</term><def><p>high-density lipoprotein cholesterol</p></def></def-item><def-item><term id="abb13">HOMA</term><def><p>Homeostasis Model Assessment</p></def></def-item><def-item><term id="abb14">IR</term><def><p>insulin resistance</p></def></def-item><def-item><term id="abb15">LDL-C</term><def><p>low-density lipoprotein cholesterol</p></def></def-item><def-item><term id="abb16">LightGBM</term><def><p>Light Gradient Boosting Machine</p></def></def-item><def-item><term id="abb17">ML</term><def><p>machine learning</p></def></def-item><def-item><term id="abb18">RF</term><def><p>random forest</p></def></def-item><def-item><term id="abb19">ROC</term><def><p>receiver operating characteristic</p></def></def-item><def-item><term id="abb20">SBP</term><def><p>systolic blood pressure</p></def></def-item><def-item><term id="abb21">SHAP</term><def><p>Shapley Additive Explanations</p></def></def-item><def-item><term id="abb22">SMOTE</term><def><p>synthetic minority over-sampling technique</p></def></def-item><def-item><term id="abb23">Sr</term><def><p>serum creatinine</p></def></def-item><def-item><term id="abb24">TBA</term><def><p>bile acids</p></def></def-item><def-item><term id="abb25">TBIL</term><def><p>total bilirubin</p></def></def-item><def-item><term id="abb26">TC</term><def><p>total cholesterol</p></def></def-item><def-item><term id="abb27">TG</term><def><p>triglycerides</p></def></def-item><def-item><term id="abb28">TP</term><def><p>total proteintotal</p></def></def-item><def-item><term id="abb29">UA</term><def><p>uric acid</p></def></def-item><def-item><term id="abb30">WC</term><def><p>waist circumference</p></def></def-item><def-item><term id="abb31">XGBoost</term><def><p>Extreme Gradient Boosting</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moller</surname><given-names>DE</given-names> </name><name name-style="western"><surname>Flier</surname><given-names>JS</given-names> </name></person-group><article-title>Insulin resistance--mechanisms, syndromes, and implications</article-title><source>N Engl J Med</source><year>1991</year><month>09</month><day>26</day><volume>325</volume><issue>13</issue><fpage>938</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1056/NEJM199109263251307</pub-id><pub-id pub-id-type="medline">1881419</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galicia-Garcia</surname><given-names>U</given-names> </name><name name-style="western"><surname>Benito-Vicente</surname><given-names>A</given-names> </name><name name-style="western"><surname>Jebari</surname><given-names>S</given-names> </name><etal/></person-group><article-title>Pathophysiology of type 2 diabetes mellitus</article-title><source>Int J Mol Sci</source><year>2020</year><month>08</month><day>30</day><volume>21</volume><issue>17</issue><fpage>32872570</fpage><pub-id pub-id-type="doi">10.3390/ijms21176275</pub-id><pub-id pub-id-type="medline">32872570</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H</given-names> </name><name name-style="western"><surname>Saeedi</surname><given-names>P</given-names> </name><name name-style="western"><surname>Karuranga</surname><given-names>S</given-names> </name><etal/></person-group><article-title>IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045</article-title><source>Diabetes Res Clin Pract</source><year>2022</year><month>01</month><volume>183</volume><issue>109119</issue><fpage>109119</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2021.109119</pub-id><pub-id pub-id-type="medline">34879977</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parcha</surname><given-names>V</given-names> </name><name name-style="western"><surname>Heindl</surname><given-names>B</given-names> </name><name name-style="western"><surname>Kalra</surname><given-names>R</given-names> </name><etal/></person-group><article-title>Insulin resistance and cardiometabolic risk profile among nondiabetic American young adults: insights from NHANES</article-title><source>J Clin Endocrinol Metab</source><year>2022</year><month>01</month><day>1</day><volume>107</volume><issue>1</issue><fpage>e25</fpage><lpage>e37</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgab645</pub-id><pub-id pub-id-type="medline">34473288</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>XY</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>WY</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>ZJ</given-names> </name></person-group><article-title>The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome a-mong subjects with different glucose tolerance</article-title><source>Chin J Diabetes</source><year>2004</year><access-date>2025-06-02</access-date><issue>3</issue><fpage>31</fpage><lpage>35</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://europepmc.org/article/CBA/587039">https://europepmc.org/article/CBA/587039</ext-link></comment></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeFronzo</surname><given-names>RA</given-names> </name><name name-style="western"><surname>Tobin</surname><given-names>JD</given-names> </name><name name-style="western"><surname>Andres</surname><given-names>R</given-names> </name></person-group><article-title>Glucose clamp technique: a method for quantifying insulin secretion and resistance</article-title><source>Am J Physiol</source><year>1979</year><month>09</month><volume>237</volume><issue>3</issue><fpage>E214</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.1979.237.3.E214</pub-id><pub-id pub-id-type="medline">382871</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonora</surname><given-names>E</given-names> </name><name name-style="western"><surname>Targher</surname><given-names>G</given-names> </name><name name-style="western"><surname>Alberiche</surname><given-names>M</given-names> </name><etal/></person-group><article-title>Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity</article-title><source>Diabetes Care</source><year>2000</year><month>01</month><volume>23</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2337/diacare.23.1.57</pub-id><pub-id pub-id-type="medline">10857969</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>R</given-names> </name><name name-style="western"><surname>Dong</surname><given-names>Q</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>X</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>J</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>J</given-names> </name></person-group><article-title>A cost-effective, machine learning-driven approach for screening arterial functional aging in a large-scale Chinese population</article-title><source>Front Public Health</source><year>2024</year><volume>12</volume><issue>1365479</issue><fpage>1365479</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2024.1365479</pub-id><pub-id pub-id-type="medline">38572001</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>W</given-names> </name><name name-style="western"><surname>Xue</surname><given-names>M</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Yao</surname><given-names>H</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names> </name></person-group><article-title>A machine learning based framework to identify and classify non-alcoholic fatty liver disease in a large-scale population</article-title><source>Front Public Health</source><year>2022</year><volume>10</volume><issue>846118</issue><fpage>846118</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.846118</pub-id><pub-id pub-id-type="medline">35444985</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birk</surname><given-names>N</given-names> </name><name name-style="western"><surname>Matsuzaki</surname><given-names>M</given-names> </name><name name-style="western"><surname>Fung</surname><given-names>TT</given-names> </name><etal/></person-group><article-title>Exploration of machine learning and statistical techniques in development of a low-cost screening method featuring the global diet quality score for detecting prediabetes in rural India</article-title><source>J Nutr</source><year>2021</year><month>10</month><day>23</day><volume>151</volume><issue>12 Suppl 2</issue><fpage>110S</fpage><lpage>118S</lpage><pub-id pub-id-type="doi">10.1093/jn/nxab281</pub-id><pub-id pub-id-type="medline">34689190</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N</given-names> </name><name name-style="western"><surname>Fan</surname><given-names>F</given-names> </name><name name-style="western"><surname>Geng</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Evaluating the risk of hypertension in residents in primary care in Shanghai, China with machine learning algorithms</article-title><source>Front Public Health</source><year>2022</year><volume>10</volume><issue>984621</issue><fpage>984621</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.984621</pub-id><pub-id pub-id-type="medline">36267989</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaribeygi</surname><given-names>H</given-names> </name><name name-style="western"><surname>Maleki</surname><given-names>M</given-names> </name><name name-style="western"><surname>Sathyapalan</surname><given-names>T</given-names> </name><name name-style="western"><surname>Jamialahmadi</surname><given-names>T</given-names> </name><name name-style="western"><surname>Sahebkar</surname><given-names>A</given-names> </name></person-group><article-title>Pathophysiology of physical inactivity-dependent insulin resistance: a theoretical mechanistic review emphasizing clinical evidence</article-title><source>J Diabetes Res</source><year>2021</year><volume>2021</volume><issue>7796727</issue><fpage>7796727</fpage><pub-id pub-id-type="doi">10.1155/2021/7796727</pub-id><pub-id pub-id-type="medline">34660812</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Guolin Ke</surname><given-names>QM</given-names> </name><name name-style="western"><surname>Finley</surname><given-names>T</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>T</given-names> </name><etal/></person-group><article-title>LightGBM: a highly efficient gradient boosting decision tree advances in neural information processing systems</article-title><conf-name>Advances in Neural Information Processing Systems 30 (NIPS 2017)</conf-name><conf-date>Dec 4-9, 2017</conf-date><conf-loc>California, USA</conf-loc></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>SF</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>CT</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>WJ</given-names> </name><name name-style="western"><surname>Lee</surname><given-names>CL</given-names> </name></person-group><article-title>Development and validation of an insulin resistance model for a population without diabetes mellitus and its clinical implication: a prospective cohort study</article-title><source>EClinicalMedicine</source><year>2023</year><month>04</month><volume>58</volume><fpage>101934</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101934</pub-id><pub-id pub-id-type="medline">37090441</pub-id></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>CL</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>WJ</given-names> </name><name name-style="western"><surname>Tsai</surname><given-names>SF</given-names> </name></person-group><article-title>Development and validation of an insulin resistance model for a population with chronic kidney disease using a machine learning approach</article-title><source>Nutrients</source><year>2022</year><month>07</month><day>9</day><volume>14</volume><issue>14</issue><fpage>2832</fpage><pub-id pub-id-type="doi">10.3390/nu14142832</pub-id><pub-id pub-id-type="medline">35889789</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names> </name><name name-style="western"><surname>Zeng</surname><given-names>T</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Development and validation of machine learning-augmented algorithm for insulin sensitivity assessment in the community and primary care settings: a population-based study in China</article-title><source>Front Endocrinol</source><year>2024</year><volume>15</volume><issue>1292346</issue><fpage>38332892</fpage><pub-id pub-id-type="doi">10.3389/fendo.2024.1292346</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S</given-names> </name><name name-style="western"><surname>Kim</surname><given-names>C</given-names> </name><name name-style="western"><surname>Wu</surname><given-names>X</given-names> </name></person-group><article-title>Development and validation of an insulin resistance predicting model using a machine-learning approach in a population-based cohort in Korea</article-title><source>Diagnostics (Basel)</source><year>2022</year><month>01</month><day>16</day><volume>12</volume><issue>1</issue><fpage>212</fpage><pub-id pub-id-type="doi">10.3390/diagnostics12010212</pub-id><pub-id pub-id-type="medline">35054379</pub-id></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngueta</surname><given-names>G</given-names> </name><name name-style="western"><surname>Laouan-Sidi</surname><given-names>EA</given-names> </name><name name-style="western"><surname>Lucas</surname><given-names>M</given-names> </name></person-group><article-title>Does waist circumference uncorrelated with BMI add valuable information?</article-title><source>J Epidemiol Community Health</source><year>2014</year><month>09</month><volume>68</volume><issue>9</issue><fpage>849</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1136/jech-2014-204005</pub-id><pub-id pub-id-type="medline">24915975</pub-id></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloomgarden</surname><given-names>ZT</given-names> </name></person-group><article-title>American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC</article-title><source>Diabetes Care</source><year>2003</year><month>03</month><volume>26</volume><issue>3</issue><fpage>933</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.3.933</pub-id><pub-id pub-id-type="medline">12610060</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pei</surname><given-names>D</given-names> </name><name name-style="western"><surname>Kuo</surname><given-names>SW</given-names> </name><name name-style="western"><surname>Wu</surname><given-names>DA</given-names> </name><etal/></person-group><article-title>The relationships between insulin resistance and components of metabolic syndrome in Taiwanese Asians</article-title><source>Int J Clin Pract</source><year>2005</year><month>12</month><volume>59</volume><issue>12</issue><fpage>1408</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1111/j.1368-5031.2005.00661.x</pub-id><pub-id pub-id-type="medline">16351672</pub-id></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names> </name><name name-style="western"><surname>Gungor</surname><given-names>N</given-names> </name><name name-style="western"><surname>Bacha</surname><given-names>F</given-names> </name><name name-style="western"><surname>Arslanian</surname><given-names>S</given-names> </name></person-group><article-title>Insulin resistance: link to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth</article-title><source>Diabetes Care</source><year>2007</year><month>08</month><volume>30</volume><issue>8</issue><fpage>2091</fpage><lpage>2097</lpage><pub-id pub-id-type="doi">10.2337/dc07-0203</pub-id><pub-id pub-id-type="medline">17475936</pub-id></nlm-citation></ref><ref id="ref22"><label>22</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceddia</surname><given-names>RB</given-names> </name><name name-style="western"><surname>Somwar</surname><given-names>R</given-names> </name><name name-style="western"><surname>Maida</surname><given-names>A</given-names> </name><name name-style="western"><surname>Fang</surname><given-names>X</given-names> </name><name name-style="western"><surname>Bikopoulos</surname><given-names>G</given-names> </name><name name-style="western"><surname>Sweeney</surname><given-names>G</given-names> </name></person-group><article-title>Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells</article-title><source>Diabetologia</source><year>2005</year><month>01</month><volume>48</volume><issue>1</issue><fpage>132</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1007/s00125-004-1609-y</pub-id><pub-id pub-id-type="medline">15619075</pub-id></nlm-citation></ref><ref id="ref23"><label>23</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chuang</surname><given-names>CC</given-names> </name><name name-style="western"><surname>Bumrungpert</surname><given-names>A</given-names> </name><name name-style="western"><surname>Kennedy</surname><given-names>A</given-names> </name><etal/></person-group><article-title>Grape powder extract attenuates tumor necrosis factor &#x03B1;-mediated inflammation and insulin resistance in primary cultures of human adipocytes</article-title><source>J Nutr Biochem</source><year>2011</year><month>01</month><volume>22</volume><issue>1</issue><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2009.12.002</pub-id><pub-id pub-id-type="medline">20382011</pub-id></nlm-citation></ref><ref id="ref24"><label>24</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>P</given-names> </name><name name-style="western"><surname>Stumvoll</surname><given-names>M</given-names> </name></person-group><article-title>Fatty acids and insulin resistance in muscle and liver</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2005</year><month>12</month><volume>19</volume><issue>4</issue><fpage>625</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2005.07.003</pub-id><pub-id pub-id-type="medline">16311221</pub-id></nlm-citation></ref><ref id="ref25"><label>25</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drew</surname><given-names>BG</given-names> </name><name name-style="western"><surname>Rye</surname><given-names>KA</given-names> </name><name name-style="western"><surname>Duffy</surname><given-names>SJ</given-names> </name><name name-style="western"><surname>Barter</surname><given-names>P</given-names> </name><name name-style="western"><surname>Kingwell</surname><given-names>BA</given-names> </name></person-group><article-title>The emerging role of HDL in glucose metabolism</article-title><source>Nat Rev Endocrinol</source><year>2012</year><month>01</month><day>24</day><volume>8</volume><issue>4</issue><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.235</pub-id><pub-id pub-id-type="medline">22271188</pub-id></nlm-citation></ref><ref id="ref26"><label>26</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>T</given-names> </name><name name-style="western"><surname>Onuma</surname><given-names>T</given-names> </name><name name-style="western"><surname>Takebe</surname><given-names>K</given-names> </name><name name-style="western"><surname>Kral</surname><given-names>JG</given-names> </name></person-group><article-title>The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects</article-title><source>Int J Obes Relat Metab Disord</source><year>1995</year><month>12</month><volume>19</volume><issue>12</issue><fpage>841</fpage><lpage>845</lpage><pub-id pub-id-type="medline">8963349</pub-id></nlm-citation></ref><ref id="ref27"><label>27</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchesini</surname><given-names>G</given-names> </name><name name-style="western"><surname>Brizi</surname><given-names>M</given-names> </name><name name-style="western"><surname>Bianchi</surname><given-names>G</given-names> </name><etal/></person-group><article-title>Nonalcoholic fatty liver disease: a feature of the metabolic syndrome</article-title><source>Diabetes</source><year>2001</year><month>08</month><volume>50</volume><issue>8</issue><fpage>1844</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.2337/diabetes.50.8.1844</pub-id><pub-id pub-id-type="medline">11473047</pub-id></nlm-citation></ref><ref id="ref28"><label>28</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spoto</surname><given-names>B</given-names> </name><name name-style="western"><surname>Pisano</surname><given-names>A</given-names> </name><name name-style="western"><surname>Zoccali</surname><given-names>C</given-names> </name></person-group><article-title>Insulin resistance in chronic kidney disease: a systematic review</article-title><source>Am J Physiol Renal Physiol</source><year>2016</year><month>12</month><day>1</day><volume>311</volume><issue>6</issue><fpage>F1087</fpage><lpage>F1108</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00340.2016</pub-id><pub-id pub-id-type="medline">27707707</pub-id></nlm-citation></ref></ref-list></back></article>